Off-Label Targeted Cancer Therapy Review Could Aid Compendia Evaluation
Executive Summary
A CMS-sponsored review of the data available to support off-label use of targeted cancer therapies could help evaluate whether the drug compendia used by Medicare as the basis for determining Part B coverage for off-label cancer drugs incorporate the most current data